#USA #Jersey City #RADICAVA #Shionogi #Tanabe Pharma

Tanabe Pharma America Transfers RADICAVA Business to Shionogi

In a pivotal development within the pharmaceutical industry, Tanabe Pharma America, Inc. (TPA) has finalized the transfer of its RADICAVA (edaravone) business to Shionogi Inc. (SI). This decision underscores TPA’s commitment to developing innovative solutions for patients facing rare diseases, particularly amyotrophic lateral sclerosis (ALS).

Key Details of the Transfer

The transfer, which was previously announced on December 22, 2025, marks a significant milestone in TPA's strategy to enhance the RADICAVA brand's market presence and sustainability. As of April 1, 2026, all rights related to RADICAVA, including intellectual property and marketing rights in key markets, will officially transition to Shionogi. For select regions, the transfer will occur in phases, adhering to specific regulatory protocols.

President Yasutoshi Kawakami expressed pride in bringing RADICAVA to patients with ALS and emphasized that this transition heralds both an exciting new chapter for TPA and an opportunity to direct resources toward innovative scientific discoveries. “We look forward to advancing our pipeline of investigational treatments for challenging diseases,” he stated.

Commitment to Patients

Throughout the transfer process, TPA's primary focus has been ensuring that there will be no disruption in care for RADICAVA patients and their families. The company has meticulously planned this transition to uphold the continuity of product availability and support services. Patients can expect seamless access to the medication, along with all previously established patient support services remaining operational.

Unchanged Supply Chain

There are no anticipated changes to the existing supply chain for RADICAVA, ensuring that patients can continue their treatment without interruption. Claims processes for adverse events related to RADICAVA will also proceed as before, providing a reliable channel for both healthcare providers and patients to raise concerns.

A Future-Forward Approach

The strategic transfer to Shionogi is poised to bolster the financial stability of TPA while sharpening their focus on growth. By enabling the company to concentrate on pioneering treatments, both Tanabe Pharma and Shionogi are preparing to make significant strides in addressing unmet medical needs.

The overarching mission of TPA is encapsulated in their motto, "Creating hope for all facing illness." This guiding principle will remain at the forefront as they endeavor to innovate through both internal research initiatives and collaborative partnerships.

Insights into RADICAVA ORS

Initially approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022, RADICAVA ORS has gained recognition for its role in ALS treatment. The FDA granted Orphan Drug Exclusivity to RADICAVA ORS in 2024, due to its contribution to patient care through a more accessible oral suspension compared to its intravenous predecessor. The medication serves as a pivotal therapy option, allowing patients to follow a structured dosing schedule that enhances compliance and convenience.

With a robust heritage of research dating back to 2001, Tanabe Pharma has significantly contributed to the development of RADICAVA. This transfer of the business unit to Shionogi marks the next stage in a journey that has seen the product enter numerous markets globally, helping thousands of patients gain access to effective treatments.

As TPA continues to advocate for innovation in the medical sector, the collaboration with Shionogi is anticipated to expand the impact of RADICAVA, further enhancing the quality of life for those affected by ALS. Together, they are committed to bridging the gaps in treatment access and fostering advances in medical science that resonate across patient communities worldwide.